Diltiazem hydrochloride: adverse event reports filed with FDA

6,082

reports as suspect product

0% of all reports · about 270 a year

504

reports, 12 months to June 2026

793 in the 12 months before

88.3%

marked serious by the reporter

87.7% across the class

35%

record death among outcomes, as reported

2,126 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Diltiazem hydrochloride reports recording the termmedian drug in calcium channel blocker

1. Dyspnoeashortness of breath15%911
2. Painpain, site not specified14.9%905
3. Falla fall13.8%837
4. Hypotensionlow blood pressure12.6%766
5. Fatiguetiredness11.3%685
6. Toxicity to various agentspoisoning or toxic effect of one or more substances10.9%660
7. Arthralgiajoint pain10.7%648
8. Mobility decreasedreduced ability to move about10.5%637
9. Pruritusitching10.2%622
10. Pyrexiafever9.9%600
11. Dizzinesslight-headedness or unsteadiness9.8%596
12. Condition aggravatedthe condition being treated got worse9.6%585
13. Headachehead pain9.6%583
14. Hypersensitivityan allergic-type reaction9.6%582
15. Diarrhoealoose or frequent stools8.9%543
16. Drug ineffectivethe medicine did not work as expected8.8%534
17. Balance disorderproblems with balance8.8%533
18. Insomniadifficulty sleeping8.6%525
19. Impaired healingslow healing8.5%518
20. Asthmaasthma8.5%515
21. Constipationconstipation8.3%504
22. Drug interactionan interaction between medicines8.2%497
23. Orthostatic hypotension8.1%495
24. Cognitive disorderproblems with thinking or memory8.1%492
25. Pain in extremitypain in an arm or leg8%487
26. Wheezingwheezing7.9%482
27. Nauseafeeling sick7.9%478
28. Off label useused for a purpose or in a way not on the label7.9%478
29. Rashskin rash7.8%476
30. Decreased appetitereduced appetite7.8%472

Top 30 of 970 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the calcium channel blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 76,049 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 37.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 6,082 reports.

Drugs most often listed in the same reports

Other products listed in reports where Diltiazem hydrochloride is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the calcium channel blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Diltiazem hydrochloride as a suspect or interacting product; reports listing it only as a concomitant medication (8,147) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.